merck glp 1 agonist Comparing Ozempic, Wegovy and Other GLP-1 Drugs GLP-1 receptor agonists in the

As use of these drugs is expected to expand to other health conditions, there is a pressing need for physical therapists to adapt their practices to support the long-term health goals of their patients and ensure optimal patient outcomes

Starting July 1, 2026, the Medicare GLP-1 Bridge program will give eligible Part D plan members access to Foundayo , Wegovy (injection or tablet), or Zepbound (KwikPen ) weight loss medications for a $50 copayment for each 30-day supply

If ongoing trials continue to deliver positive results, triple agonist therapies for diabetes may represent the next major evolution in treating obesity, type 2 diabetes, and related metabolic diseases

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy